second reviewer was up to 3% more sensitive than the first. In the ovarian cancer, anti-infectives, hyperlipidemia, and clinical breast cancer reviews, the second reviewer was up to 2% more specific than the first; all were significant differences apart from the clinical breast cancer review. In the cases where the second reviewer was less sensitive or specific than the first, these differences were non-significant. CONCLUSIONS: While first and second reviewers tend to have similar sensitivity in including citations, second reviewers tend to be more accurate at excluding citations. This may be explained by the fact that, since more caution is exercised in excluding citations than including them, reviewers may wait until they have gained sufficient experience to make this decision. 
University of Göttingen, Göttingen, Germany OBJECTIVES: To determine 12-months administrative prevalence rate of tic disorders (TD) and Tourette syndrome (TS), as well as their coexistence with ADHD in a large German community sample, against the background of the clinical importance of this association. METHODS: Data for patients with a diagnosis of any tic disorder (F95, ICD-10), Tourette disorder (F95.2), or ADHD (F90.0 and/or F90.1) were extracted from the Nordbaden claims database, covering the complete subpopulation insured by Statutory Health Insurance (2.238 million lives in 2003; for comparison: total German population insured by SHI in 2003, 70.2 million) in Nordbaden in South-Western Germany (representing 82% of the total regional population). RESULTS: A total of 3,618 patients with a diagnosis of any TD (hereof, 215 with TS) and 11,875 patients with ADHD were identified, corresponding to overall administrative prevalence rates (across all age groups) of 0.16% (TD), 0.01% (TS), and 0.53% (ADHD). Males were generally more often afflicted with any of the disorders analyzed than females (TD, 0.19% versus 0.13% for females; TS, 0.02% versus 0.01%; ADHD, 0.83% versus 0.27%). TD and TS were most prevalent among children 7-12 years (0.79% and 0.04%, respectively), and were significantly associated with presence of ADHD. ADHD was reported in 11.2% of children age Յ12 years with TD (boys, 15.4%; girls, 4.5%), compared to 3.1% (boys, 4.4%; girls, 1.7%) in the community covered. Among adolescents (age 13-18 years), a diagnosis of ADHD was tenfold more likely in patients with TD (15.1%; boys, 18.5%; girls, 7.7%) compared with the community group (1.5%; boys, 2.3%; girls, 0.7%). CONCLUSIONS: These data extend the epidemiological database by providing for the first time information from Germany on the administrative prevalence of TD, TS, and ADHD, as well as their coexistence, hereby highlighting the relevance of taking comorbidity into account when designing health care utilization and burden of disease studies. The majority (50-80%) of patients with generalized anxiety disorder (GAD) suffer from a variety of sleep problems. The objective of this study was to measure the direct effect of anxiolytic treatment and, separately, its indirect effect mediated by anxiety symptoms on sleep disturbance in patients with GAD. METHODS: Data were obtained from an 8-week, doubleblind, randomized, flexible-dose, placebo-and active-control study in 372 GAD patients. Patients were assigned to pregabalin (300-600 mg/day), venlafaxine XR (75-225 mg/day), or placebo. Anxiety symptoms were measured by clinicianadministered HAM-A scale at baseline and on weeks 1-4, 6, and 8 and sleep disturbances were measured using the 4-item sleep disturbance subscale on Medical Outcomes Study Sleep Scale (MOS-SS), a validated patient-reported outcome measure. Statistical mediation modeling was used to estimate the direct effects of pregabalin and venlafaxine XR (relative to placebo) and the indirect effects via anxiety symptoms, the mediator variable, as measured by HAM-A total score. All available data from the trial were used in the statistical analyses. RESULTS: Patients were predominantly female (61%) and had a mean age of 41 years. Path coefficients for direct and indirect (mediated) paths for patients in the pregabalin group indicated less sleep disturbance with treatment. Fifty-three percent of the reduction in sleep disturbance was due to the direct effect of pregabalin (p = 0.007). The remainder of the reduction in sleep disturbance (47%, p = 0.015) was mediated via anxiety symptoms. In contrast, there was no difference in sleep disturbance (p = 0.58) between patients treated with venlafaxine XR or placebo. CONCLUSIONS: The underlying relationships between treatment, anxiety symptoms, and sleep disturbance are explicitly described and partitioned through mediation modeling. About half of the total improvement in sleep disturbance was identified as being due to the direct effect of pregabalin independent of an effect on anxiety symptoms. 4 Janssen Pharmaceutica, Beerse, Belgium OBJECTIVES: To evaluate preliminary treatment outcomes of Russian patients enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) followed up for three months after initiating treatment with risperidone long-acting injectable (RLAI). METHODS: e-STAR is an international, prospective, observational study of schizophrenia patients initiated on RLAI. Psychiatric hospitalisations and medication use are collected retrospectively for one year and prospectively every three months for two years. Clinical and functioning outcomes, which are measured by the Clinical Global Impression Severity (CGI-S) Scale and the Global Assessment of Functioning (GAF) Scale, respectively, are assessed prospectively every three months for two years. McNemar's test and paired-t test were used to evaluAbstracts A579
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